Climb Bio, Inc. (CLYM)
NASDAQ: CLYM · Real-Time Price · USD
10.36
-0.51 (-4.69%)
At close: Nov 13, 2026, 4:00 PM EST
9.62
-0.74 (-7.16%)
After-hours: Nov 13, 2026, 7:30 PM EST
Climb Bio Market Cap
Climb Bio has a market cap or net worth of $608.53 million as of November 13, 2026. It is the 13,007th most valuable company in the world and the 2,564th biggest in the United States. Its market cap has increased by 364.83% in one year.
Market Cap
608.53M
Enterprise Value
381.97M
1-Year Change
364.83%
Global Rank
Country Rank
#2,564 United States
Category
ChartMarket Cap Chart
Since August 10, 2021, Climb Bio's market cap has increased from $403.20M to $608.53M, an increase of 50.93%. That is a compound annual growth rate of 8.13%.
| Date | Market Cap | % Change |
|---|---|---|
| Nov 13, 2026 | 608.53M | 218.64% |
| Dec 31, 2025 | 190.98M | 57.83% |
| Dec 31, 2024 | 121.00M | 62.54% |
| Dec 29, 2023 | 74.45M | -23.65% |
| Dec 30, 2022 | 97.50M | -64.90% |
| Dec 31, 2021 | 277.76M | -31.11% |
| Aug 10, 2021 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Zevra Therapeutics | 709.30M |
| DBV Technologies | 702.82M |
| Iambic Therapeutics | 700.58M |
| ArriVent BioPharma | 697.74M |
| Prime Medicine | 693.83M |
| Immix Biopharma | 692.24M |
| 4D Molecular Therapeutics | 688.34M |
| Design Therapeutics | 681.99M |